World Scientific
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.

The Changing Demography and Treatment of Nasopharyngeal Carcinoma in Melbourne from 1985–2000

    https://doi.org/10.1142/S0219836303000025Cited by:1 (Source: Crossref)

    Incidence: Nasopharyngeal cancer (NPC) is a rare disease in Caucasians and is commonly WHO Type 1 (squamous cell carcinoma) histology. NPC is endemic in southern China (the Guangdong Province), Hong Kong and Taiwan, and is usually WHO Type 3 (undifferentiated) histology. These differing patient cohorts and different staging systems have hampered the rate of progress in optimizing the management of NPC patients.

    Changing demographics: Melbourne's population demographics have changed significantly since 1985. Our NPC population currently bridges the endemic and non-endemic populations.

    Treatment: There have been major improvements in radiation therapy techniques. The optimal conformal radiation technique(s) to be used if IMRT is not available is discussed. Concurrent chemotherapy and radiation therapy (chemoradiation) is the current standard of treatment in NPC. The role of additional sequential chemotherapy is controversial. A randomized trial comparing induction chemotherapy and chemoradiation versus chemoradiation alone would be very informative.